Phase 2 N=104 Efficacy and Dose Ranging Study of Seroguard
Adhesion
Primary: Number of Participants With Reduction of Adhesions Number by 3 or More — 1; 1; 10; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=43 A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Uterine Fibroids
Primary: Percentage of Participants in Amenorrhea at the End of Treatment Course 1 — 58.33; 70.59; 0.0 percentage of participants — p=0.0008
Phase 2 N=352 A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
Huntington's Disease
Primary: Change From Baseline in UHDRS-TMS at Week 52 — 1.3; 1.4; 2.0; 11.0 units on a scale — p=0.4853
Phase 2 N=421 Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma
Asthma
Primary: Mean Change From Baseline in Clinic Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 — 0.1289; 0.3046; 0.3130 Liters — p=<0.001
Phase 2 N=51 Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia · Neuropathy · Neuropathic Pain
Primary: Daily Total Dose of Oral Morphine (mg/kg/Day). — 0.38267; 0.27433; 0.43685; 0.31816 mg/kg/day
Phase 2 N=35 Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma
Biliary Cancer · Cholangiocarcinoma
Primary: Progression Free Survival Rate at Five Months — 69 percentage of participants
Phase 2 N=21 Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
Bone Cancer · Chondrosarcoma · Ewing's Sarcoma
Primary: T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects — 7.3; 7.7 milliseconds
Phase 2 N=42 Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871
Chronic Obstructive Pulmonary Disease COPD
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) — 0.168; 0.267; 0.007 L — p=<0.001
Phase 2 N=88 A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Primary: Proportion of Participants With at Least One Adverse Events (AEs) or Serious AEs (SAEs) in 1 Year — 35; 40 Participants
Phase 2 N=10 Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers
Aging · Skin Abnormalities
Primary: Change in Common Deletion (CD) Value in DNA of Skin Biopsy Sample — -84; 217 percent change
Phase 2 N=244 A Study to Evaluate the Efficacy, Safety and Tolerability of MIV-711 in Osteoarthritis Patients
Osteoarthritis, Knee
Primary: Numeric Rating Scale (NRS) Average Target Knee Pain Score at Week 26 — -1.7; -1.5; -1.3 score — p=0.4055
Phase 2 N=16 Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
Hormone-Resistant Prostate Cancer · Prostate Adenocarcinoma · Recurrent Prostate Carcinoma
Primary: cTTP
Phase 2 N=52 Combination Vaccination Before HIV Treatment Interruption
HIV Infections
Primary: Time to Detectable Virus in the Remune Plus ALVAC Group and the Placebo Group — 24.5; 13.5 days
Phase 2 N=74 LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
Breast Neoplasms
Primary: Percentage of Participants With Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version (RECIST) 1.1 — 18; 31 Percentage of participants
Phase 2 N=42 Effectiveness of BBT-I and Zopiclone for Chronic Insomnia
Insomnia Chronic
Primary: Insomnia Severity Index — 18.6; 18.9; 13.1; 14.0 units on a scale